MD1003 (high-dose biotin) for the treatment of progressive multiple sclerosis: A randomised, double-blind, placebo-controlled study

2016286 citationsJournal Articlebronze Open Access

Authors

MD1003 achieves sustained reversal of MS-related disability in a subset of patients with progressive MS and is well tolerated.

Good health and well-being

Published in: Multiple Sclerosis Journal

Volume 22, Issue 13, pp. 1719-1731

Field-Weighted Citation Impact: 35.64